Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL
about
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL
description
clinical trial
@en
klinisch onderzoek
@nl
name
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL
@en
type
label
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL
@en
prefLabel
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL
@en
P4844
P1050
P1476
Phase 1 Trial of Rituximab, Id ...... ymphocytic Leukemia (RIVe-CLL)
@en
P1813
RIVe-CLL
@en
P3098
NCT03639324
P580
2019-03-30T00:00:00Z
P582
2022-03-30T00:00:00Z